SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)--February 24, 2026-- ...

The risk of disease progression or death was reduced by 79% with nivolumab/ipilimumab compared with chemotherapy. The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved the Idylla CDx MSI test — a fully automated, “sample-to-result” companion diagnostic — for ...

A French prospective real-life cohort confirmed the favorable prognosis of nonmetastatic microsatellite instability (MSI) colorectal cancers. These cancers nevertheless entailed a high risk for ...

Total neoadjuvant therapy followed by total mesorectal excision and selective lateral lymph node dissection for locoregionally advanced low rectal cancer: A phase III randomized controlled trial ...

While immune checkpoint inhibitors (anti-PD-1 +/- anti-CTLA-4) are approved as first line treatment for microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC), many patients ...

Utility of gene expression–based cancer classification in diagnosis of malignant peritoneal mesothelioma (MPeM): Filling in the gaps in standard pathologic work-up for a rare cancer. This is an ASCO ...

Microsatellite instability (MSI), which results from defects in the DNA mismatch repair system, is an important biomarker in colorectal cancer. While the MSI-high (MSI-H) status predicts response to ...

Findings showed in the ITT population, zanzalintinib plus atezolizumab statistically significantly reduced the risk of death compared with regorafenib. Topline data were announced from a phase 3 trial ...